Annual Total Long Term Liabilities
$170.31 M
-$12.22 M-6.70%
31 December 2023
Summary:
Adaptimmune Therapeutics annual total long term liabilities is currently $170.31 million, with the most recent change of -$12.22 million (-6.70%) on 31 December 2023. During the last 3 years, it has risen by +$99.47 million (+140.42%). ADAP annual total long term liabilities is now -15.28% below its all-time high of $201.04 million, reached on 31 December 2021.ADAP Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$173.99 M
+$30.64 M+21.37%
30 September 2024
Summary:
Adaptimmune Therapeutics quarterly total long term liabilities is currently $173.99 million, with the most recent change of +$30.64 million (+21.37%) on 30 September 2024. Over the past year, it has increased by +$40.63 million (+30.46%). ADAP quarterly long term liabilities is now -13.46% below its all-time high of $201.04 million, reached on 31 December 2021.ADAP Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADAP Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -6.7% | +30.5% |
| 3 y3 years | +140.4% | +143.7% |
| 5 y5 years | +3045.8% | +651.0% |
ADAP Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -15.3% | +140.4% | -13.5% | +143.7% |
| 5 y | 5 years | -15.3% | +3045.8% | -13.5% | +651.0% |
| alltime | all time | -15.3% | -13.5% |
Adaptimmune Therapeutics Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $173.99 M(+21.4%) |
| June 2024 | - | $143.35 M(-14.3%) |
| Mar 2024 | - | $167.22 M(-1.8%) |
| Dec 2023 | $170.31 M(-6.7%) | $170.31 M(+27.7%) |
| Sept 2023 | - | $133.36 M(-4.9%) |
| June 2023 | - | $140.21 M(-0.3%) |
| Mar 2023 | - | $140.57 M(-23.0%) |
| Dec 2022 | $182.54 M(-9.2%) | $182.54 M(+19.5%) |
| Sept 2022 | - | $152.78 M(-11.5%) |
| June 2022 | - | $172.72 M(-9.3%) |
| Mar 2022 | - | $190.50 M(-5.2%) |
| Dec 2021 | $201.04 M(+183.8%) | $201.04 M(+181.5%) |
| Sept 2021 | - | $71.41 M(+1.4%) |
| June 2021 | - | $70.44 M(-1.0%) |
| Mar 2021 | - | $71.12 M(+0.4%) |
| Dec 2020 | $70.84 M(+200.6%) | $70.84 M(+4.3%) |
| Sept 2020 | - | $67.92 M(+2.8%) |
| June 2020 | - | $66.06 M(-4.8%) |
| Mar 2020 | - | $69.39 M(+194.5%) |
| Dec 2019 | $23.56 M | $23.56 M(+1.7%) |
| Sept 2019 | - | $23.17 M(-4.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2019 | - | $24.24 M(-11.4%) |
| Mar 2019 | - | $27.35 M(+405.2%) |
| Dec 2018 | $5.41 M(+40.7%) | $5.41 M(+38.7%) |
| Sept 2018 | - | $3.90 M(+0.4%) |
| June 2018 | - | $3.89 M(+0.1%) |
| Mar 2018 | - | $3.88 M(+0.9%) |
| Dec 2017 | $3.85 M(-86.3%) | $3.85 M(+0.8%) |
| Sept 2017 | - | $3.82 M(-84.4%) |
| June 2017 | - | $24.53 M(-4.7%) |
| Mar 2017 | - | $25.74 M(-8.4%) |
| Dec 2016 | $28.10 M(+22.5%) | $28.10 M(+40.7%) |
| Sept 2016 | - | $19.98 M(-10.9%) |
| June 2016 | - | $22.43 M(-1.5%) |
| Mar 2016 | - | $22.78 M(+69.3%) |
| Dec 2015 | $22.94 M(+54.1%) | - |
| Sept 2015 | - | $13.46 M(>+9900.0%) |
| June 2015 | $14.88 M(>+9900.0%) | - |
| Dec 2014 | - | $0.00(0.0%) |
| June 2014 | $0.00(0.0%) | $0.00 |
| June 2013 | $0.00(0.0%) | - |
| June 2012 | $0.00 | - |
FAQ
- What is Adaptimmune Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual total long term liabilities year-on-year change?
- What is Adaptimmune Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly long term liabilities year-on-year change?
What is Adaptimmune Therapeutics annual total long term liabilities?
The current annual total long term liabilities of ADAP is $170.31 M
What is the all time high annual total long term liabilities for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual total long term liabilities is $201.04 M
What is Adaptimmune Therapeutics annual total long term liabilities year-on-year change?
Over the past year, ADAP annual total long term liabilities has changed by -$12.22 M (-6.70%)
What is Adaptimmune Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of ADAP is $173.99 M
What is the all time high quarterly long term liabilities for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly total long term liabilities is $201.04 M
What is Adaptimmune Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, ADAP quarterly total long term liabilities has changed by +$40.63 M (+30.46%)